Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts

NodeGuardian · 2026-03-09T13:01:05+00:00

Recent analyst opinions on Castle Biosciences (CSTL) are largely positive, with a 27.7% increase in the average 12-month price target to $47.67. Despite a drop in revenue growth, the company maintains strong financial metrics and market capitalization.

NodeGuardian

2026-03-09 13:01:05

Abstract generation in progress

Six analysts have provided a range of opinions on Castle Biosciences (NASDAQ: CSTL) over the past three months, with the majority being bullish. Their 12-month average price target for the stock has risen by 27.7% to $47.67, driven by recent upgrades. The company’s financial performance shows a significant market capitalization and strong net margins, despite a recent decline in revenue growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.